Nuclear Medicine Equipment Market Size & Share Analysis - Growth Trends And Forecast (2025 - 2030)

Global Nuclear Medicine Equipment Market Trends and Insights

Rising Burden of Oncology & Cardiology Cases

Cancer incidence is projected to climb 47% by 2050, pushing clinicians toward molecular techniques that can track tiny treatment responses undetectable on CT or MR.^{[1]Society of Nuclear Medicine and Molecular Imaging, “CMS Adjusts Nuclear Medicine Reimbursement Policy,” snmmi.org} The 2024 FDA nod for flurpiridaz F-18 now lets care teams perform stress PET studies with higher accuracy and lower isotope decay risk, expanding nuclear cardiology reach. Because aging populations drive both cancer and coronary disease, hospitals upgrade tracer inventories and schedule additional imaging slots to keep pace with combined oncology and cardiology demand. PET-based perfusion studies, though costlier than SPECT, gain favor as evidence mounts for better outcomes in complex coronary artery disease. Consequently, long-term procedure volume growth remains resilient regardless of short-term macroeconomic swings, reinforcing the nuclear medicine equipment market as an essential service.

Rapid Adoption of Hybrid PET/CT & SPECT/CT Scanners

Hybrid scanners fuse metabolic and anatomical data in one acquisition, eliminating registration errors and halving patient throughput time. The Biograph Trinion PET/CT, cleared in 2024, illustrates this shift with air-cooled detectors that cut power use by 46% while delivering 239-ps time-of-flight performance. Health systems view these gains as strategic because faster scans increase daily capacity without expanding staff, a critical benefit in tight labor markets. Hybrid systems also simplify reporting by synchronizing voxel-level anatomical landmarks with tracer uptake, improving diagnostic confidence in oncology staging and therapy monitoring. Long axial FOV designs, such as the uEXPLORER, cover the entire body in under 60 seconds and reduce radiopharmaceutical dose by more than 80%. These operational and clinical advantages position hybrid platforms as the growth engine of the nuclear medicine equipment market.

Reimbursement Expansion for Molecular Imaging in OECD

The 2025 CMS rule finally decouples radiopharmaceuticals priced above USD 630 from packaged imaging payments, removing the financial penalty that curtailed PET adoption in community sites. High-value agents like piflufolastat F-18 for prostate cancer can now reach more patients because hospitals are reimbursed for both the scan and the tracer. Parallel reforms are moving through European systems, with NICE expanding coverage for amyloid and PSMA imaging in 2024. These policy shifts create a feedback loop: broader access yields richer clinical datasets, which in turn support further guideline inclusion. As payers accept molecular imaging’s cost–benefit balance, procedure volumes in mid-tier hospitals rise, pushing the nuclear medicine equipment market toward wider geographic diffusion.

Government Isotope-Production Investments

Mo-99 shortages in late 2024 exposed the fragility of aging reactors and triggered significant funding for domestic production. SHINE Technologies secured USD 50 million to finish the Chrysalis plant, forecast to supply more than one-third of global Mo-99 from US soil. Legislators see isotope independence as both a public-health and national-security goal, channeling grants and tax credits into low-enriched-uranium processes that lower proliferation risk. Domestic output stabilizes tracer availability, giving hospitals confidence to expand nuclear medicine programs without fear of supply interruptions. The same facilities will also generate lutetium-177 for theranostic agents, aligning with the nuclear medicine equipment market’s trend toward combined diagnostic and therapeutic workflows.

Commercial Rollout of CZT Digital SPECT Cameras

CZT detectors convert gamma photons directly to charge, boosting energy resolution and quadrupling count sensitivity compared with conventional NaI crystals. Clinical trials show a 64.3% normal scan classification rate for cardiac studies against 28.6% on legacy systems.^{[2]Gytis Aleksa, “Comparative Analysis of Cardiac SPECT Myocardial Perfusion Imaging: Full-Ring Solid-State Detectors Versus Dedicated Cardiac Fixed-Angle Gamma Camera,” Medicina, mdpi.com} Lower dose requirements and ten-minute scan times meet value-based care goals, while compact gantries fit older suites without major construction. As unit costs fall, mid-size hospitals purchase CZT cameras for coronary artery disease evaluation, migrating some volume from PET in resource-constrained settings. Vendor partnerships, such as Spectrum Dynamics with Hermes Medical Solutions, couple hardware with AI-enhanced software to streamline post-processing. These collaborative ecosystems reinforce the appeal of digital SPECT and propel segment growth inside the broader nuclear medicine equipment market.

Long-Axial FOV PET/CT Enabling Ultra-Low-Dose Workflows

Total-body PET/CT systems extend axial coverage past 180 cm, allowing a single continuous bed motion that captures dynamic tracer kinetics across all organs. Researchers can now study whole-body pharmacokinetics with femto-mol sensitivity using just a fraction of traditional doses, which proves invaluable for pediatrics and longitudinal drug trials. Early adopters include academic centers that leverage ultra-low-dose protocols to broaden study enrollment without the ethical concerns associated with high radiation. Over time, as capital costs decline and reimbursement codes align, community cancer centers are expected to adopt these scanners for routine staging. The technology’s capacity for unprecedented temporal resolution positions it as a future standard, establishing another platform for revenue acceleration in the nuclear medicine equipment market.

High Capital & Service Contracts for Scanners

A state-of-the-art PET/CT can cost USD 2-4 million, and annual service fees often reach 10% of the purchase price, straining the budgets of smaller hospitals. Required shielding, HVAC upgrades, and IT interfaces double project outlays, making return-on-investment calculations difficult. Financing models are evolving; Positron’s rental plan for the NeuSight PET-CT reduces upfront cash yet still locks providers into long service terms. Complex software stacks require vendor engineers for routine updates, and downtime penalties cut into margins. These realities slow penetration in mid-income nations, tempering overall growth in the nuclear medicine equipment market.

Supply-Chain Fragility of Short-Lived Radio-Isotopes

The October 2024 reactor delay in Europe reduced Mo-99 exports and left clinics scrambling for Tc-99m doses, illustrating the vulnerability of just-in-time isotope logistics. Because Mo-99’s 66-hour half-life prevents stockpiling, any transport hiccup cancels patient appointments within days. Cargo flight delays, customs hold-ups, and weather disruptions compound risk. Alternative production via cyclotrons or linear accelerators remains years from large-scale viability. Until redundancy improves, supply shocks periodically curtail scan volumes and dampen confidence in the nuclear medicine equipment market.

Segment Analysis

By Product Type: Hybrid Systems Outpace Legacy Modalities

SPECT scanners accounted for 52.3% of revenue in 2024, as they remain affordable and reliable for routine cardiac and bone studies. Hybrid PET/CT systems, on the other hand, are expected to expand at a 7.9% CAGR as clinicians prioritize precision diagnostics. The nuclear medicine equipment market benefits from hybrid devices, which elevate clinical confidence while optimizing workflow. Advances such as AI-assisted protocol selection and iterative reconstruction increase sensitivity while reducing doses, thereby reinforcing demand. In a parallel trend, planar cameras remain steady for thyroid and sentinel-node imaging, although their share declines as 3-D modalities proliferate. 

Across the forecast, vendors embed digital detectors and cloud-enabled analytics into all scanner classes. GE HealthCare’s launch of the flurpiridaz-compatible PET protocol in 2025 prompts mid-tier hospitals to add PET suites, boosting the nuclear medicine equipment market size for high-resolution cardiac imaging. Long-axial-FOV PET/CT systems extend use cases to dynamic tracer studies and whole-body dosimetry, capturing new research budgets and increasing revenue diversity.

Note: Segment shares of all individual segments available upon report purchase

By Detector Technology: Digital Transition Gains Pace

NaI Anger cameras delivered 68.1% of 2024 shipments, reflecting decades of a large installed base and a low unit price. Yet CZT technology is advancing at a 12.8% CAGR and increasingly captures replacement cycles. Providers adopt CZT because higher energy resolution distinguishes overlapping isotopes in dual-isotope protocols, enhancing cardiac diagnostics. SiPM-based PET detectors also see rising orders for their picosecond timing, which sharpens image quality. Analog PMT configurations remain prevalent in cost-sensitive settings, helping to sustain baseline volume in the nuclear medicine equipment market. 

Clinical trials underline CZT superiority, especially in coronary perfusion, where count sensitivity directly informs treatment plans. Declining semiconductor costs and multi-vendor competition compress prices, widening access. Ongoing R&D into CdTe and HgI₂ substrates suggests further improvements in resolution. Integration with AI-powered denoising software means future systems deliver higher clarity at lower administered doses, solidifying the digital transition within the nuclear medicine equipment market.

By Application: Oncology Dominates While Neurology Accelerates

Oncology held a 41.6% share in 2024 as precision medicine protocols rely on PET tracers for tumor characterization and therapy monitoring. The introduction of PSMA agents and total-body PET scanning widens clinical staging capabilities. Neurology is projected to grow at a 9.4% CAGR, propelled by amyloid and tau imaging for Alzheimer’s research and evolving reimbursement in memory clinics. Cardiology remains central thanks to perfusion studies that guide revascularization decisions, although some volume migrates to cardiac CT in low-risk cohorts. 

Theranostic pathways blend imaging with targeted therapy, deepening oncology’s revenue stream in the nuclear medicine equipment market. Agents such as lutetium-177 PSMA provide both diagnostic scans and therapeutic doses, creating cyclical imaging demand through treatment courses. In neurology, Lantheus’ acquisition of NAV-4694 propels beta-amyloid detection into community settings, expanding scan volumes beyond academic centers. The combination of aging demographics and tracer innovation ensures sustained multi-segment growth.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospitals Lead but Outpatient Centers Surge

Hospitals accounted for 62.5% of scans in 2024 owing to comprehensive infrastructure, emergency capacity, and oncology programs. Specialty clinics, however, are expected to grow at an 8.6% CAGR because payers favor outpatient sites for cost control. Diagnostic imaging centers optimize scheduling and staffing to maximize scanner utilization, reducing per-scan cost. Academic facilities remain innovation hubs where new tracers and ultra-low-dose protocols enter practice, seeding future demand across the nuclear medicine equipment market. 

Mobile units bridge rural gaps by transporting SPECT or PET systems on scheduled routes, thereby broadening geographic access without requiring permanent installations. The growth of freestanding theranostic centers highlights a shift toward integrated care models, where imaging and therapy converge under one roof. These facilities rely on a consistent isotope supply and specialized staff, reinforcing both supply-chain and workforce priorities in the nuclear medicine equipment market.

Geography Analysis

North America generated 34.7% of 2024 revenue following the implementation of CMS reimbursement reform and ongoing research funding, which accelerated equipment renewals. Providers in the United States quickly integrate AI tools to streamline protocol selection, while Canadian hospitals invest in cyclotrons to achieve self-reliance in isotope production. Mexico upgrades imaging fleets in metropolitan areas to attract medical tourists, adding incremental volumes. 

Europe ranks second in market size, anchored by Germany’s university-hospital network and the Netherlands’ isotope reactors. However, the 2024 Mo-99 shortage exposed reliance on single reactors and spurred EU grants for diversified production. The United Kingdom’s NHS embeds molecular imaging pathways in national cancer plans, stabilizing procedure volumes even during fiscal tightening. Central and Eastern European nations are experiencing double-digit growth as they modernize their diagnostic infrastructure, thereby generating new demand for nuclear medicine equipment. 

The Asia Pacific is the fastest-growing region, with a 7.2% CAGR, driven by rising chronic disease incidence and government capacity-building programs. China operates more than 1,200 nuclear medicine sites serving millions of patients each year.^{[3]Journal of Nuclear Medicine, “Cardiac CZT SPECT Comparative Study,” jnm.snmjournals.org} Japan’s mature ecosystem now benefits from GE HealthCare’s acquisition of Nihon Medi-Physics, which secures domestic tracer supply. India scales PET-CT capacity in tier-two cities, and Australia backs theranostic trials targeting rare cancers. These initiatives compound into robust regional momentum for the nuclear medicine equipment market.